Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P49914

UPID:
MTHFS_HUMAN

ALTERNATIVE NAMES:
5,10-methenyl-tetrahydrofolate synthetase

ALTERNATIVE UPACC:
P49914; H3BQ75

BACKGROUND:
The enzyme 5-formyltetrahydrofolate cyclo-ligase, alternatively known as 5,10-methenyl-tetrahydrofolate synthetase, is integral to folate metabolism, facilitating the biosynthesis of critical biomolecules. It ensures the proper flow of carbon units in the folate-mediated one-carbon metabolism, crucial for nucleotide and amino acid synthesis.

THERAPEUTIC SIGNIFICANCE:
Its association with the neurodevelopmental disorder featuring microcephaly, epilepsy, and hypomyelination underscores the enzyme's significance in neurological health. Exploring the functions of 5-formyltetrahydrofolate cyclo-ligase offers promising avenues for developing targeted therapies for related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.